The effect of 9-β-D-arabinofuranosyl-2-fluoroadenine and 1-β-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 3, 1996, Pages 261-268

  Loughlin, Susan ^a   Gandhi, Varsha ^a   Plunkett, William ^a   Zwelling, Leonard A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute leukemia; Antimetabolite; Topoisomerase II

Indexed keywords

AMSACRINE; ANTIMETABOLITE; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); FLUDARABINE; GYRASE INHIBITOR; MITOXANTRONE;

ACUTE LEUKEMIA; ARTICLE; CELL CYCLE PHASE; CELL CYCLE S PHASE; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CYTARABINE; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOBLOTTING; LEUKEMIA, MYELOCYTIC, ACUTE; MITOXANTRONE; PROTEIN BINDING; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 0029893574     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050480     Document Type: Article

References (33)

1. Bakic M, Chan D, Andersson BS, Beran M, Silberman L, Estey E, Ricketts L, Zwelling LA (1987) Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4′-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells. Biochem Pharmacol 36:4067
2. Chow K, Ross WE (1987) Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 7:3119
3. Chresta CM, Hicks R, Hartley JA, Souhami RL (1992) Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine. Cancer Chemother Pharmacol 31:139
4. Chu MY, Fisher GA (1965) Comparative studies of leukemia cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol 14:333
5. 3H arabinoside and its effect on the murine leukemia cells (L5178Y). Biochem Pharmacol 17:753
6. Colly LP, Peters WG, Arnentsen-Honders MW, Willemze R (1990) Cell kinetics after high dose cytosine arabinoside in patients with acute myelocytic leukemia: Blut 60:76
7. Ellis AL, Zwelling LA (1993) Resistance to topoisomerase II-directed agents. In: Hickman JA, Tritton T (Eds) Frontiers in pharmacology: cancer chemotherapy. Blackwell Scientific, Oxford, p 200
8. Ellis A, Randolph JK, Conway BR, Gewirtz DA (1990) Biochemical lesions in DNA associated with the antiproliferative effects of mitoxantrone in the hepatoma cell. Biochem Pharmacol 39:1549
9. Endicott JA, Ling V (1989) The biochemistry of p-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58:137
10. Estey E, Adlakha RC, Hittelman WN, Zwelling LA (1987) Cell cycle stage dependent variations in drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity. Biochemistry 26:4338
11. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Realing MJ (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9:343
12. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Freireich EJ, Deisseroth A, Keating MJ (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671
13. Feldman E, Gandhi V, Plunkett W, Nowak B, Estey E, Kantarjian H, O'Brien S, Rios MB, Keating MJ (1992) Sequential administration of fludarabine, ara-C, and mitoxantrone enhances topoisomerase II-DNA complex formation and has efficacy in acute leukemia. Blood 80:208
14. Fountzilas G, Inoue S, Ohnuma T (1990) Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture. Leukemia 4:321
15. Gandhi V, Plunkett W (1988) Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48:329
16. Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116
17. Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 10:109
18. Grant S (1990) Biochemical modulation of cytosine arabinoside. Pharmacol Ther 48:29
19. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zwelling LA (1991) Identification of a point mutation in the topoisomerase II gene from human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51:4729
20. Hsiang Y-H, Wu H-Y, Liu LF (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48:3230
21. Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ (1986) High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4:1079
22. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ (1986) Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81:387
23. Keating MJ, McCredie KB, Bodey GP, Smith, TL, Gehan EA, Freireich EJ (1982) Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248:2481
24. Kohn KW, Ewig RAG, Erickson LC, Zwelling L (1981) Measurement of strand breaks and cross-links by alkaline clution. In: Friedberg EC, Hanawalt PC (eds) DNA repair: a laboratory manual of research techniques. Marcel Dekker, New York, p 379
25. Mayes J, Hinds M, Soares L, Altschuler E, Kim P, Zwelling LA (1993) Further characterization of an amsacrine-resislant line of HL-60 human leukemia cells and its topoisomerase II: effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. Biochem Pharmacol 46:699
26. Schrecker AW, Urshel MJ (1968) Metabolism of 1-β-D-arabinofuranosylcytosine in leukemia L1210. Studies with intact cells. Cancer Res 28:793
27. Smets LA, Taminiau J, Hahlen K, Waal de F, Behrendt H (1983) Cell kinetic responses in childhood acute nonlymphocytic leukemia during high-dose therapy with cytosine arabinoside. Blood 61:79
28. Sundman-Engberg B (1993) Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo. Leuk Res 17:347
29. Swinnen LJ, Barnes DM, Fisher SG, Albain KS, Fisher RI, Erickson LC (1989) 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum (II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res 49:1383
30. Wang LM, Rhinehardt-Clark A, Capizzi RL (1991) The basis for pharmacological synergy between mitoxantrone and ara-C (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 32:A2348
31. Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nichols M, Kohn KW (1981) Protein-associated DNA strand breaks in L1210 cells treated with the DNA intercalating agents, 4′-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) and adriamycin. Biochemistry 20:6553
32. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radclifle A, Beran M, Blick M (1989) Characterization of an Amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem264:16411
33. Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radclifle A, Seligman M, Li L, Farquhar D (1991) The cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II-reactive DNA intercalating agents. Evidence for two topoisomerase II-directed drug actions. Biochemistry 30:4048